Tivic Health enters $50M equity line with Tumim Stone Capital; pre-funded warrant issued

Valion Bio, Inc.

Common Stock Purchase Agreement allows Tivic to sell up to $50M of common stock to Tumim Stone Capital at 97% or 95% of VWAP.
Pre-funded warrant for 437,012 shares at $0.0001 per share issued as commitment fee; warrants exercisable immediately.
Exchange Cap set at 506,848 shares (19.99% of outstanding) unless average sale price equals or exceeds $1.02 per share.
Daily maximum draw is $1M (one-day valuation) or $2.5M (three-day valuation) with volume limits of 15% or 40% of daily volume.
Registration Rights Agreement filed to register resale of shares issued under the Purchase Agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Valion Bio, Inc. entered into Common Stock Purchase Agreement with Tumim Stone Capital, LLC valued at Up to $50,000,000 of newly issued shares of Common Stock (effective 2026-02-06).

Action: entry
Agreement: equity purchase
Counterparty: Tumim Stone Capital, LLC
Value: Up to $50,000,000 of newly issued shares of Common Stock
Effective: 2026-02-06

Exact text from the filing

On February 6, 2026, Tivic Health Systems, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Tumim Stone Capital, LLC, a Delaware limited liability company (the “Investor”).

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-000877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.